These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Bassetti C; Gugger M; Bischof M; Mathis J; Sturzenegger C; Werth E; Radanov B; Ripley B; Nishino S; Mignot E Sleep Med; 2003 Jan; 4(1):7-12. PubMed ID: 14592354 [TBL] [Abstract][Full Text] [Related]
3. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. Oka Y; Inoue Y; Kanbayashi T; Kuroda K; Miyamoto M; Miyamoto T; Ikeda A; Shimizu T; Hishikawa Y; Shibasaki H Sleep; 2006 Nov; 29(11):1439-43. PubMed ID: 17162990 [TBL] [Abstract][Full Text] [Related]
4. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Mignot E; Lammers GJ; Ripley B; Okun M; Nevsimalova S; Overeem S; Vankova J; Black J; Harsh J; Bassetti C; Schrader H; Nishino S Arch Neurol; 2002 Oct; 59(10):1553-62. PubMed ID: 12374492 [TBL] [Abstract][Full Text] [Related]
5. Exploring the cytokine and endocrine involvement in narcolepsy. Okun ML; Giese S; Lin L; Einen M; Mignot E; Coussons-Read ME Brain Behav Immun; 2004 Jul; 18(4):326-32. PubMed ID: 15157949 [TBL] [Abstract][Full Text] [Related]
6. Peripheral leptin levels in narcoleptic patients. Dahmen N; Engel A; Helfrich J; Manderscheid N; Löbig M; Forst T; Pfützner A; Tonn P Diabetes Technol Ther; 2007 Aug; 9(4):348-53. PubMed ID: 17705690 [TBL] [Abstract][Full Text] [Related]
7. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Nishino S; Kanbayashi T Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155 [TBL] [Abstract][Full Text] [Related]
8. Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. Nakamura M; Kanbayashi T; Sugiura T; Inoue Y J Sleep Res; 2011 Mar; 20(1 Pt 1):45-9. PubMed ID: 20642748 [TBL] [Abstract][Full Text] [Related]
9. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. Sturzenegger C; Bassetti CL J Sleep Res; 2004 Dec; 13(4):395-406. PubMed ID: 15560774 [TBL] [Abstract][Full Text] [Related]
10. [A case of HLA-DR2, DQw1 negative post-traumatic narcolepsy]. Maeda M; Tamaoka A; Hayashi A; Mizusawa H; Shoji S Rinsho Shinkeigaku; 1995 Jul; 35(7):811-3. PubMed ID: 8777810 [TBL] [Abstract][Full Text] [Related]
11. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Hong SC; Lin L; Jeong JH; Shin YK; Han JH; Lee JH; Lee SP; Zhang J; Einen M; Mignot E Sleep; 2006 Nov; 29(11):1429-38. PubMed ID: 17162989 [TBL] [Abstract][Full Text] [Related]
12. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Martínez-Rodríguez JE; Lin L; Iranzo A; Genis D; Martí MJ; Santamaria J; Mignot E Sleep; 2003 May; 26(3):287-90. PubMed ID: 12749547 [TBL] [Abstract][Full Text] [Related]
13. HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Honda Y; Juji T; Matsuki K; Naohara T; Satake M; Inoko H; Someya T; Harada S; Doi Y Sleep; 1986; 9(1 Pt 2):133-42. PubMed ID: 3010426 [TBL] [Abstract][Full Text] [Related]
14. Impaired histaminergic neurotransmission in children with narcolepsy type 1. Franco P; Dauvilliers Y; Inocente CO; Guyon A; Villanueva C; Raverot V; Plancoulaine S; Lin JS CNS Neurosci Ther; 2019 Mar; 25(3):386-395. PubMed ID: 30225986 [TBL] [Abstract][Full Text] [Related]
15. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Dahmen N; Kasten M; Wieczorek S; Gencik M; Epplen JT; Ullrich B Cephalalgia; 2003 Feb; 23(1):14-9. PubMed ID: 12534574 [TBL] [Abstract][Full Text] [Related]
19. Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype. A study at the serological and genomic level. Wilner A; Steinman L; Lavie P; Peled R; Friedmann A; Brautbar C Hum Immunol; 1988 Jan; 21(1):15-22. PubMed ID: 2896649 [TBL] [Abstract][Full Text] [Related]
20. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis. de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]